KR102742219B1 - 5'-포스포로티올레이트 mRNA 5'-말단 (캡) 유사체, 이를 포함하는 mRNA, 이를 얻기 위한 방법, 및 이의 용도 - Google Patents

5'-포스포로티올레이트 mRNA 5'-말단 (캡) 유사체, 이를 포함하는 mRNA, 이를 얻기 위한 방법, 및 이의 용도 Download PDF

Info

Publication number
KR102742219B1
KR102742219B1 KR1020187021714A KR20187021714A KR102742219B1 KR 102742219 B1 KR102742219 B1 KR 102742219B1 KR 1020187021714 A KR1020187021714 A KR 1020187021714A KR 20187021714 A KR20187021714 A KR 20187021714A KR 102742219 B1 KR102742219 B1 KR 102742219B1
Authority
KR
South Korea
Prior art keywords
mrna
cap
phosphorothiolate
sma
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187021714A
Other languages
English (en)
Korean (ko)
Other versions
KR20180100595A (ko
Inventor
야첵 제미에리티
카자 팩-다브로우스카
블라제이 보이착
마레크 바라노우스키
안나 노윅카
조아나 코왈스카
파웰 시코르스키
마르친 와르민스키
Original Assignee
유니웨시테트 바르샤바
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니웨시테트 바르샤바 filed Critical 유니웨시테트 바르샤바
Publication of KR20180100595A publication Critical patent/KR20180100595A/ko
Application granted granted Critical
Publication of KR102742219B1 publication Critical patent/KR102742219B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C07H1/04—Introducing polyphosphoric acid radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020187021714A 2016-01-29 2017-01-27 5'-포스포로티올레이트 mRNA 5'-말단 (캡) 유사체, 이를 포함하는 mRNA, 이를 얻기 위한 방법, 및 이의 용도 Active KR102742219B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLPL415967 2016-01-29
PL415967A PL415967A1 (pl) 2016-01-29 2016-01-29 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie
PCT/IB2017/050447 WO2017130151A1 (en) 2016-01-29 2017-01-27 5'-phosphorothiolate mrna 5'-end (cap) analogs, mrna comprising the same, method of obtaining and uses thereof

Publications (2)

Publication Number Publication Date
KR20180100595A KR20180100595A (ko) 2018-09-11
KR102742219B1 true KR102742219B1 (ko) 2024-12-13

Family

ID=58387852

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187021714A Active KR102742219B1 (ko) 2016-01-29 2017-01-27 5'-포스포로티올레이트 mRNA 5'-말단 (캡) 유사체, 이를 포함하는 mRNA, 이를 얻기 위한 방법, 및 이의 용도

Country Status (11)

Country Link
US (1) US11066436B2 (enExample)
EP (1) EP3408276B1 (enExample)
JP (1) JP7144050B2 (enExample)
KR (1) KR102742219B1 (enExample)
CN (1) CN109071589A (enExample)
AU (1) AU2017211693B2 (enExample)
CA (1) CA3011663C (enExample)
EA (1) EA038834B1 (enExample)
ES (1) ES2879802T3 (enExample)
PL (2) PL415967A1 (enExample)
WO (1) WO2017130151A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112020002327T5 (de) * 2019-05-10 2022-07-14 New England Biolabs, Inc. Chemisches verkappen für matrizenwechsel
CN110907358B (zh) * 2019-12-09 2022-08-30 福建师范大学 一种光微流微泡腔铅离子传感器的实现装置及方法
PL432884A1 (pl) * 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
CN113234780A (zh) * 2020-08-20 2021-08-10 深圳市瑞吉生物科技有限公司 一种Cap2结构5′帽子类似物及其制备方法和应用
CN116368226A (zh) 2020-09-04 2023-06-30 维乎医疗有限公司 用于加帽rna的组合物和方法
WO2023167880A2 (en) * 2022-03-01 2023-09-07 Verve Therapeutics, Inc. Compositions and methods for capping rnas
CN114685588B (zh) * 2022-05-05 2024-03-29 江苏申基生物科技有限公司 一种含开环核苷结构的起始加帽寡核苷酸引物
CN116143855B (zh) * 2022-11-08 2023-11-28 江苏申基生物科技有限公司 一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用
EP4464713A1 (en) 2023-05-18 2024-11-20 Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii Circular rna analogs, preparation and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546424A (ja) 2005-06-28 2008-12-25 アジェンコート パーソナル ジェノミクス コーポレイション 修飾ポリヌクレオチドを作製する方法および配列決定する方法
JP2011522542A (ja) 2008-06-06 2011-08-04 ウニヴェルシテ ワルシャワスキ ｍＲＮＡＣＡＰ類似体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072561B (zh) * 2007-06-19 2017-12-22 路易斯安那州州立大学及农业机械学院管理委员会 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途
EP2281579A1 (en) * 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
EP2970351B1 (en) * 2013-03-14 2017-09-13 Translate Bio, Inc. Ribonucleic acids with 4'-thio-modified nucleotides and related methods
HRP20200250T1 (hr) 2013-08-08 2020-05-29 The Scripps Research Institute Metoda site-specifično enzimsko obilježavanje nukleinskih kiselina in vitro ugradnjom neprirodnih nukleotida

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546424A (ja) 2005-06-28 2008-12-25 アジェンコート パーソナル ジェノミクス コーポレイション 修飾ポリヌクレオチドを作製する方法および配列決定する方法
JP2011522542A (ja) 2008-06-06 2011-08-04 ウニヴェルシテ ワルシャワスキ ｍＲＮＡＣＡＰ類似体

Also Published As

Publication number Publication date
AU2017211693B2 (en) 2021-09-09
US20190300563A1 (en) 2019-10-03
CA3011663A1 (en) 2017-08-03
JP2019504837A (ja) 2019-02-21
EP3408276B1 (en) 2021-04-07
AU2017211693A1 (en) 2018-08-09
ES2879802T3 (es) 2021-11-23
JP7144050B2 (ja) 2022-09-29
US11066436B2 (en) 2021-07-20
CA3011663C (en) 2023-10-31
EA038834B1 (ru) 2021-10-26
EA201891429A1 (ru) 2019-02-28
EP3408276A1 (en) 2018-12-05
CN109071589A (zh) 2018-12-21
PL415967A1 (pl) 2017-07-31
WO2017130151A1 (en) 2017-08-03
PL3408276T3 (pl) 2021-10-25
KR20180100595A (ko) 2018-09-11

Similar Documents

Publication Publication Date Title
KR102742219B1 (ko) 5'-포스포로티올레이트 mRNA 5'-말단 (캡) 유사체, 이를 포함하는 mRNA, 이를 얻기 위한 방법, 및 이의 용도
CN113603739B (zh) 一种加帽类似物及其应用
AU2009256131B2 (en) mRNA cap analogs
EP2346883B1 (en) Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
JP5998326B2 (ja) 新規核酸プロドラッグおよびその使用方法
JP2021531022A (ja) 環状ポリリボヌクレオチドを含む組成物及びその使用
CA3167563A1 (en) Novel mrna 5'-end cap analogs modified within phosphate residues, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule or peptide
AU2008265683A1 (en) Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
US20250059537A1 (en) Therapeutic oligonucleotides having an inter-nucleoside amide linkage
HK1260250A1 (en) 5′-phosphorothiolate mrna 5′-end (cap) analogs, mrna comprising the same, method of obtaining and uses thereof
US20170224832A9 (en) Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
HK1242326A (en) Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
PL214850B1 (pl) Cząsteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub białka

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180726

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220107

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240322

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240928

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241209

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241210

End annual number: 3

Start annual number: 1

PG1601 Publication of registration